According to a document submitted to the U.S. Securities and Exchange Commission, biotechnology company Regenxbio Inc has confirmed that it will continue, under its existing sublicensing agreement with pharmaceutical giant GlaxoSmithKline, to pay the latter the relevant amounts received from sublicensees.

According to a document submitted to the U.S. Securities and Exchange Commission, biotechnology company Regenxbio Inc has confirmed that it will continue, under its existing sublicensing agreement with pharmaceutical giant GlaxoSmithKline, to pay the latter the relevant amounts received from sublicensees.

老虎证券2026/03/20 21:33

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This arrangement clarifies Regenxbio's financial obligations in the commercialization process of related intellectual property, ensuring the continued fulfillment of the agreement terms. This move reflects the stability of the long-term cooperative relationship between both parties and adherence to the established contract terms.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

You may also like

Trending news

Crypto prices